🏢 官网IRCSTLCodex · 实盘不做把握 9/10
北京时间·🕒 发布 19:00:00时区推断·⟳ 抓取 19:01:02·⚡ 决策 07-22 19:02:38 +1m36s·97.2 天前
Castle Biosciences将参加Canaccord Genuity年度成长会议并做公司概览演讲
该公告仅披露管理层将参加投资者会议并提供公司概览，没有新增订单、业绩、产品获批、监管进展或商业化量化信息。
📄 原文CSTL↗ 原文
Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference
Press Releases News & Events IR Events Presentations In The Media Annual Meeting Email Alerts Castle Biosciences to Pre…
不做 Castle Biosciences（CSTL.US）
例行投资者会议出席公告，没有新增方向性内容或可量化基本面增量，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-22 · 扩散 low · price-in 风险 low ↗
关键理由
- 该公告仅披露管理层将参加投资者会议并提供公司概览，没有新增订单、业绩、产品获批、监管进展或商业化量化信息。
主要风险
- 若会议当天披露超预期经营数据或新产品进展，需由后续新信号重新研判。
原文全文
展开原文 · 2,067 字
Press Releases
News & Events
IR Events
Presentations
In The Media
Annual Meeting
Email Alerts
Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference
July 22, 2026 7:00am EDT
FRIENDSWOOD, Texas
,
July 22, 2026
/PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Canaccord Genuity 46
th
Annual Growth Conference on Wednesday, Aug. 12, 2026, at 11:30 a.m. Eastern time.
A live audio webcast of the Company's presentation will be available by visiting Castle Biosciences' website at
https://ir.castlebiosciences.com/news-events/ir-events
. A replay of the webcast will be available following the conclusion of the live broadcast.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. With a primary focus in dermatologic and gastroenterological disease, we develop personalized, clinically actionable solutions that help improve disease management and patient outcomes.
We put people first—empowering patients and clinicians and informing care decisions through rigorous science and advanced molecular tests that support more confident treatment planning. To learn more, visit
www.CastleBiosciences.com
and connect with us on
LinkedIn
Instagram
Facebook
and
X
.
DecisionDx-Melanoma, DecisionDx-CM
Seq
, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, Esopredict, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UM
are trademarks of Castle Biosciences, Inc.
Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact:
Allison Marshall
amarshall@castlebiosciences.com
View original content to download multimedia:
https://www.prnewswire.com/news-releases/castle-biosciences-to-present-at-the-canaccord-genuity-46th-annual-growth-conference-302831101.html
SOURCE Castle Biosciences, Inc.
Released July 22, 2026
News & Events
IR Events
Presentations
In The Media
Annual Meeting
Email Alerts
Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference
July 22, 2026 7:00am EDT
FRIENDSWOOD, Texas
,
July 22, 2026
/PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Canaccord Genuity 46
th
Annual Growth Conference on Wednesday, Aug. 12, 2026, at 11:30 a.m. Eastern time.
A live audio webcast of the Company's presentation will be available by visiting Castle Biosciences' website at
https://ir.castlebiosciences.com/news-events/ir-events
. A replay of the webcast will be available following the conclusion of the live broadcast.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. With a primary focus in dermatologic and gastroenterological disease, we develop personalized, clinically actionable solutions that help improve disease management and patient outcomes.
We put people first—empowering patients and clinicians and informing care decisions through rigorous science and advanced molecular tests that support more confident treatment planning. To learn more, visit
www.CastleBiosciences.com
and connect with us on
and
X
.
DecisionDx-Melanoma, DecisionDx-CM
Seq
, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, Esopredict, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UM
are trademarks of Castle Biosciences, Inc.
Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact:
Allison Marshall
amarshall@castlebiosciences.com
View original content to download multimedia:
https://www.prnewswire.com/news-releases/castle-biosciences-to-present-at-the-canaccord-genuity-46th-annual-growth-conference-302831101.html
SOURCE Castle Biosciences, Inc.
Released July 22, 2026
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。